

Adami P, DiPauli J, Prapotnik M, Vetter Z, Waschgler R, Conca A. Carbamazepin Intoxikation bei Kombinationstherapie mit Olanzapin: Eine Kasuistik. *Psychopharmakotherapie* 2004; 11: 129-13

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G. The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic drug monitoring in psychiatry. *Pharmacopsychiatry* 2004; 37: 243-265

Conca A, Beraus W, König P, Waschgler R. A case of pharmacokinetic interference in comedication of clozapine and valproic acid. *Pharmacopsychiatry* 2000; 33: 234-235

Conca A, Waler M, Walpoth M, König P, Hausmann A. A case of delayed galactorrhea as an adverse event of overlapping haloperidol and clozapine administration. *Int. J Neuropsychopharmacol* 2005; 8: 303-305

El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. *Journal of Pharmacy and Pharmacology* 2004; 56: 967-975

Fehr C, Gründer G, Dahmen N, Hiemke C. Increase in serum clomipramine concentrations by valproate. *Journal of Clinical Psychopharmacology* 2000; 20: 493-494

Fric M, Laux G, Rao ML. Plasmaspiegel von Risperidon bei Alterspatienten mit Demenz. *Psychopharmakotherapie* 2004; 11: 90-94

Gerlach M, Rothenhöfer S, Mehler-Wex C, Fegert JM, Schulz E, Wewetzer Ch, Warnke A. Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie – Grundlagen und praktische Empfehlungen. *Z Kinder-Jugendpsychiatr* 2006; 34: 5-13

Gerlach M, Rothenhöfer S, Mehler-Wex C, Warnke A, Wewetzer C. Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie. *Psychopharmakotherapie* 2005; 12: 118-120

Gerlach M, Schulz E, Fegert JM. Editorial „Therapeutisches Drug-Monitoring“, eine Strategie zur Verbesserung der Arzneimittelsicherheit in der Kinder- und Jugendpsychiatrie und Psychotherapie. *Z Kinder-Jugendpsychiatr* 2005; 33: 157-158

Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Härtter S, Heuser I, Hiemke C. Paroxetine serum concentrations in depressed patients and response to treatment. *Pharmacopsychiatry* 2005; 38: 118-121

Grasmäder K, Verwohlt PL, Kühn K-U, Dragicevic A, von Widdern O, Zobel A, Hiemke C, Rietschel M, Maier W, Jaehde U, Rao ML. Population pharmacokinetic analysis of mirtazapine. *European Journal of Clinical Pharmacology* 2004; 60: 473-480

Grasmäder K, Verwohlt PL, Kühn KU, Frahnert C, Hiemke C, Dragicevic A, von Widdern O, Zobel A, Maier W, Rao ML. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. *Pharmacopsychiatry* 2005; 38: 113-117

Greiner C, Hiemke C, Bader W, Haen E. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. *Journal of Chromatography B*. 2006; Nov 15; [Epub ahead of print]

Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. *Pharmacopsychiatry* 2003; 36: 3-6

Gründer G, Siessmeier T, Piel M, Vernaleken I, Buchholz HG, Zhou Y, Hiemke C, Wong DF, Rösch F, Bartenstein P. Quantification of D2-like dopamine receptors in the human brain with ¹⁸F-Desmethoxyfallpyride. *Journal of Nuclear Medicine* 2003; 44: 109-116

Haen E. Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung. *Psychopharmakotherapie* 2005; 12: 138-142

Härtter S, Connemann B, Schönfeldt-Lecuona C, Sachse J, Hiemke C. Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole. *Journal of Clinical Psychopharmacology* 2004 ; 24: 568-571

Härtter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. *Journal of Clinical Psychopharmacology* 2001; 21: 167-174

Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. *Journal of Chromatography B* 2000; 740: 135-140

Heller S, Hiemke C, Stroba G, Rieger-Gies A, Daum-Kreysch E, Sachse J, Härtter S. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM-Service. *Therapeutic Drug Monitoring* 2004; 26: 459-461

Hiemke C, Baumann P, Laux G, Kuss HJ. Therapeutisches Drug-Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP. *Psychopharmakotherapie* 2005; 12: 166-182

Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ. Therapeutic monitoring of new antipsychotic drugs. *Therapeutic Drug Monitoring* 2004; 26: 156-160

Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Härtter S, Modai I, Ritsner M, Silver H. Fluvoxamine augmentation of olanzapine in chronic schizophrenia. Pharmacokinetic interactions and clinical response. *Journal of Clinical Psychopharmacology* 2002; 22: 502-506

Hiemke C, Sachse J, Köller J, Weigmann H, Härtter S. HPLC with column-switching for therapeutic monitoring of psychoactive drugs. *Clinical Laboratory* 2003; 27: 26-27

Kirschbaum KM, Heller S, Stroba G, Rieger-Gies A, Daum-Kreysch E, Sachse J, Härtter S, Hiemke C. Chemische Stabilität neuer Antidepressiva und Antipsychotika. *Psychopharmakotherapie* 2005; 12: 121-122

Kirschbaum KM, Müller MJ, Zernig G, Saria A, Mobascher A, Malevani J, Hiemke C. Therapeutic Monitoring of Aripiprazole using HPLC with column-switching and spectrophotometric detection. *Clinical Chemistry* 2005; 51: 1718-172

König P, Conca A, Mathis B, Staska K, Veraar M und Waschgler R. Sinn oder Unsinn der Serumspiegel von Psychopharmaka. *Neuropsychiatrie* 1999; 13: 178-189

Kornhuber J, Retz W, Riederer P. Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? *Journal of Neural Transmission* 1995 (Suppl); 46: 315-323

Kornhuber J, Riederer P. Wirklatenz von Neuroleptika und Antidepressiva durch langsame Aufnahme in das Hirngewebe. In Möller HJ, Müller-Spahn F, Kurtz G, Hrsg. Aktuelle Perspektiven der Biologischen Psychiatrie. Wien, New York: Springer; 1996. p. 286-289

Kornhuber J, Weigmann H, Röhrich J, Wiltfang J, Bleich S, Meineke I, Zöchling R, Härtter S, Riederer P, Hiemke C. Region specific distribution of levomepromazine in the human brain. *Journal of Neural Transmission* 2006; 113: 387-397

Lange-Asschenfeldt CH, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. *Journal of Clinical Psychopharmacology* 2002; 22: 440-441

Laux G. Klinisch-therapeutische Wahl des Antidepressivums und Optimierung einer laufenden Behandlung. In Bauer M, Berghöfer A, Adli M, Hrsg. Akute und therapieresistente Depressionen. 2.Aufl. Berlin: Springer; 2005. p. 165-172

Laux G. Psychopharmakologische Behandlung. In Leuzinger-Bohleber M, Hau S, Deserno H (Hrsg) Depression – Pluralismus in Praxis und Forschung. Göttingen: Vandenhoeck & Ruprecht; 2005. p. 192-208

Laux G. Plasmaspiegelbestimmung (Therapeutisches Drug-Monitoring) und Pharmakogenetik. In Laux G, Dietmaier O. Praktische Psychopharmakotherapie. München: Urban & Fischer; 2006

Mann K, Bisdas S, Hiemke C. Therapeutisches Drug-Monitoring von Antidepressiva und stationäre Verweildauer von psychiatrischen Patienten. *Psychopharmakotherapie* 2005; 12: 134-138

Mann K, Hiemke C, Lotz J, Schmidt LG, Lackner KJ, Bates DW. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. *Journal of Clinical Psychopharmacology* 2006; 26: 671-673

Mann K, Hiemke C, Schmidt LG, Bates DW. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. *Therapeutic Drug Monitoring* 2006; 28: 83-88

Messer T, Schmauss M. Therapeutisches Drug Monitoring von Psychopharmaka. Sinnvolle Ergänzung oder Spielerei? *MMW-Fortschr. Med. Sonderheft 2 / 2006*

Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions? *Pharmacopsychiatry* 2003; 36: 98-104

Müller MJ, Härtter S, Köhler D, Hiemke C. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. *Pharmacopsychiatry* 2001; 34: 27-32

Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. *Journal of Psychiatric Research* 2007; 41: 673-679

Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. *Pharmacopsychiatry* 2006; 39: 41-46

Nikisch G, Mathe AA, Baumann P. Citalopram-Plasma- und Liquorkonzentrationen. Zusammenhang mit neurobiologischen und klinischen Verlaufsparemtern. *Psychopharmakotherapie* 2005; 12: 130-134

Pfuhlmann B, Gonska S, Unterecker S, Polak T, Burger R, Riederer P. TDM von trizyklischen Antidepressiva unter naturalistischen Bedingungen. Erste Ergebnisse einer retrospektiven Analyse für Amitriptylin und Doxepin bei Klinikpatienten. *Psychopharmakotherapie* 2005; 12: 122-126

Prapotnik M, Conca A. Das Cytochrom P 450-System - Arzneimittelwechselwirkungen neuer Antidepressiva. *forum dr med* 2000; 12: 15-17

Prapotnik M, Di Pauli J, Vetter Z, König P, Conca A, Waschglar R. Antidepressant associated mania with escitalopram. *Eur Psychiatry* 2004; 19: 455-6

Prapotnik M, Di Pauli J, Waschgler R, König P, Hausmann A, Conca A. Therapeutisches Drug Monitoring von Psychopharmaka. *A CliniCum Psy* 2003; 5: 22-25

Prapotnik M, Waschgler R, König P, Moll W, Conca A. Therapeutic drug monitoring of trazodone: Are there pharmacokinetic interactions involving citalopram and fluoxetine? *Int J Clin Pharmacol Ther* 2004; 2: 120-124

Riederer P, Laux G. Therapeutic Drug Monitoring of psychotropics: report of a consensus conference. *Pharmacopsychiatry* 1992; 25: 271-272

Sachse J, Härtter S, Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. *Therapeutic Drug Monitoring* 2005; 27: 158-162

Sachse J, Härtter S, Weigmann H, Hiemke C. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. *J Chromatography B* 2003; 784: 405-410

Sachse J, Köller J, Härtter S, Hiemke C. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. *J Chromatography B* 2006; 830: 342-348

Schwarz MJ, Spellmann I, Müller-Arends A, Zach J, Müller N, Möller HJ, Riedel M. Therapeutisches Drug-Monitoring von Risperidon und 9-Hydroxyrisperidon und Therapieeffekt. *Psychopharmakotherapie* 2005; 12: 126-130

Schwarz MJ, Hiemke C, Baumann P on behalf of the AGNP-TDM Expert Group. Clinical Relevance of TDM of SSRIs. *Therapeutic Drug Monitoring* 2006; 28: 716-717

Shams El Houseny M, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. *Journal of Clinical Pharmacy and Therapeutics* 2006; 31: 493-502

Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. *Therapeutic Drug Monitoring* 2005; 26: 78-84

Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, Meyer FP. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. *Int J Clin Pharmacol Ther* 2003; 41: 3-13

Ulrich S, Danos P, Baumann B, Müller D, Lehmann D, Treuheit TO, Spieler M. Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome - an open clinical trial. *Ther Drug Monit* 2002; 24: 446-454

Ulrich S, Läuter J. A comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. *Clin Pharmacokin* 2002; 41: 853-876

Ulrich S, Neuhofer S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. *Pharmacopsychiat* 1998; 31: 163-169

Ulrich S, Northoff G, Wurthmann C, Partscht G, Pester U, Herscu H, Meyer FP. Serum levels of amitriptyline and therapeutic effect in moderate to severely, non-delusional depressed inpatients: a therapeutic window relationship. *Pharmacopsychiat* 2001; 34: 33-40

Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. *Pharmacopsychiat* 2005; 38: 171-177

Ulrich S, Schroeder I, Partscht G, Baumann P. Therapeutisches Drug Monitoring von psychotropen Pharmaka: Eine allgemeine Einführung. *Psychopharmakotherapie* 2000; 7: 2-14

Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: A review. *Clin Pharmacokin* 1998; 34: 227-263

Vernaleken I, Siessmeier T, Buchholz HG, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. *International Journal of Neuropsychopharmacology* 2004; 7: 421-430

Waschgler R, Hubmann M., Conca A, Moll W, König P. Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis. *Int J Clin Pharmacol Ther* 2002; 12: 554-559

Waschgler R, Moll W, König P, Conca A. Quantification of Venlafaxine and O Desmethylvenlafaxine in human serum by HPLC analysis. *Int J Clin Pharmacol Ther*. 2004; 42: 724-8

Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. *Therapeutic Drug Monitoring* 2001; 23: 410-413

Weigmann H, Härtter S, Maehrlein S, Kiefer W, Krämer G, Dannhardt G, Hiemke C. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column switching high performance liquid chromatography. *Journal of Chromatography B* 2001; 759: 63-71

Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, Hiemke C, Saria A.
Therapeutisches Drug-Monitoring: Typische Fehler bei der Zuweisung.
Psychopharmakotherapie 2005; 12: 143-144

Zernig G, Lechner T, Kramer-Reinstadler K, Hinterhuber H, Hiemke C, Saria A. What
the clinician still has to be reminded of. Therapeutic Drug Monitoring 2004; 26: 582